Nancy Dgetluck

811 total citations
25 papers, 608 citations indexed

About

Nancy Dgetluck is a scholar working on Pathology and Forensic Medicine, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Nancy Dgetluck has authored 25 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 6 papers in Psychiatry and Mental health and 5 papers in Molecular Biology. Recurrent topics in Nancy Dgetluck's work include Systemic Sclerosis and Related Diseases (6 papers), Nicotinic Acetylcholine Receptors Study (5 papers) and Inflammatory Myopathies and Dermatomyositis (4 papers). Nancy Dgetluck is often cited by papers focused on Systemic Sclerosis and Related Diseases (6 papers), Nicotinic Acetylcholine Receptors Study (5 papers) and Inflammatory Myopathies and Dermatomyositis (4 papers). Nancy Dgetluck collaborates with scholars based in United States, United Kingdom and Australia. Nancy Dgetluck's co-authors include Dana Hilt, Maria S. Gawryl, Richard S.E. Keefe, Michael G. Palfreyman, Sheldon Preskorn, Lance O. Bauer, Hans J. Moebius, Barbara White, Gerhard Koenig and S. Constantine and has published in prestigious journals such as Annals of the Rheumatic Diseases, Neuropsychopharmacology and Journal of Investigative Dermatology.

In The Last Decade

Nancy Dgetluck

24 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy Dgetluck United States	11	224	174	146	94	88	25	608
Brian Hunter United States	11	251 1.1×	137 0.8×	141 1.0×	73 0.8×	81 0.9×	18	843
Ganggang Peng Taiwan	5	338 1.5×	39 0.2×	62 0.4×	197 2.1×	105 1.2×	10	663
J.M. Gandon France	12	94 0.4×	93 0.5×	113 0.8×	78 0.8×	301 3.4×	22	717
Warren Logge Australia	13	92 0.4×	175 1.0×	38 0.3×	201 2.1×	56 0.6×	33	597
Vernell Williamson United States	13	447 2.0×	66 0.4×	47 0.3×	108 1.1×	58 0.7×	19	777
Andrew J. Kwilasz United States	12	90 0.4×	113 0.6×	64 0.4×	167 1.8×	53 0.6×	21	564
Manav Kapoor United States	13	300 1.3×	54 0.3×	54 0.4×	119 1.3×	48 0.5×	28	639
Brian M. Kelley United States	14	227 1.0×	77 0.4×	28 0.2×	344 3.7×	45 0.5×	22	631
Galo L. Mejia United States	14	250 1.1×	91 0.5×	41 0.3×	195 2.1×	12 0.1×	19	626
Andrew P. Ray United States	13	197 0.9×	76 0.4×	42 0.3×	163 1.7×	11 0.1×	14	649

Countries citing papers authored by Nancy Dgetluck

Since Specialization

Citations

This map shows the geographic impact of Nancy Dgetluck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Dgetluck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Dgetluck more than expected).

Fields of papers citing papers by Nancy Dgetluck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Dgetluck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Dgetluck. The network helps show where Nancy Dgetluck may publish in the future.

Co-authorship network of co-authors of Nancy Dgetluck

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Dgetluck. A scholar is included among the top collaborators of Nancy Dgetluck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Dgetluck. Nancy Dgetluck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Werth, Victoria P., S.M. Peña, Majid Zeidi, et al.. (2022). Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. Journal of Investigative Dermatology. 142(10). 2651–2659.e1. 37 indexed citations

Spiera, Robert, Masataka Kuwana, Dinesh Khanna, et al.. (2021). OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). Annals of the Rheumatic Diseases. 80. 102–103. 8 indexed citations

Werth, Victoria P., Josef Symon S. Concha, Joyce Okawa, et al.. (2021). POS0315 LONG-TERM SAFETY AND EFFICACY OF LENABASUM DURING 3 YEARS IN AN OPEN-LABEL EXTENSION (OLE) OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN DISEASE IN DERMATOMYOSITIS (DM). Annals of the Rheumatic Diseases. 80. 383–384. 2 indexed citations

Spiera, Robert, Dinesh Khanna, Masataka Kuwana, et al.. (2021). A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and Experimental Rheumatology. 39(4). 124–133. 14 indexed citations

Spiera, Robert, Laura K. Hummers, Leland W.K. Chung, et al.. (2020). Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis. Arthritis & Rheumatology. 72(8). 1350–1360. 72 indexed citations

Chmiel, James F., Patrick A. Flume, D.G. Downey, et al.. (2020). Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. Journal of Cystic Fibrosis. 20(1). 78–85. 58 indexed citations

Denton, Chris, Bradley J. Bloom, Nancy Dgetluck, Barbara White, & Robert Spiera. (2020). AB0568 BASELINE EUROPEAN PATIENT DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 3 STUDY OF SAFETY AND EFFICACY OF LENABASUM, A CB2 AGONIST, IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases. 79. 1580–1581.

Werth, Victoria P., Chester V. Oddis, Ingrid E. Lundberg, et al.. (2019). SAT0303 DESIGN OF PHASE 3 STUDY OF LENABASUM FOR THE TREATMENT OF DERMATOMYOSITIS. Annals of the Rheumatic Diseases. 78. 1228–1228. 7 indexed citations

Spiera, Robert, Laura K. Hummers, Leland W.K. Chung, et al.. (2019). OP0325 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC). Annals of the Rheumatic Diseases. 78. 245–246. 3 indexed citations

10.

Werth, Victoria P., David R. Pearson, Rui Feng, et al.. (2019). OP0241 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS (DM) SUBJECTS. Annals of the Rheumatic Diseases. 78. 199–200. 3 indexed citations

11.

Werth, Victoria P., Joyce Okawa, David R. Pearson, et al.. (2018). SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001. Annals of the Rheumatic Diseases. 77. 1111–1112. 8 indexed citations

12.

Keefe, Richard S.E., Nancy Dgetluck, Maria S. Gawryl, et al.. (2015). Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacology. 40(13). 3053–3060. 120 indexed citations

13.

Barbier, Ann, Henk W. M. Hilhorst, André van Vliet, et al.. (2014). Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies. Clinical Therapeutics. 37(2). 311–324. 39 indexed citations

14.

Keefe, Richard S.E., Vicki G. Davis, Dana Hilt, et al.. (2014). Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. European Neuropsychopharmacology. 25(2). 176–184. 48 indexed citations

15.

Hufford, Michael R., Vicki G. Davis, Dana Hilt, et al.. (2014). Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies. Schizophrenia Research. 159(1). 205–210. 13 indexed citations

16.

Preskorn, Sheldon, Maria S. Gawryl, Nancy Dgetluck, et al.. (2014). Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition. Journal of Psychiatric Practice. 20(1). 12–24. 107 indexed citations

17.

Loewen, Gordon, et al.. (2013). P3–283: EVP‐6124, an alpha7 nicotinic acetycholine receptor partial agonist, did not delay cardiac repolarization in healthy subjects. Alzheimer s & Dementia. 9(4S_Part_16). 1 indexed citations

18.

Harrison, John, Nancy Dgetluck, Maria S. Gawryl, Hans J. Moebius, & Dana Hilt. (2013). P3–285: Validation of a novel cognitive composite assessment for mild and prodromal Alzheimer's disease. Alzheimer s & Dementia. 9(4S_Part_16). 5 indexed citations

19.

Goldfischer, Evan R., John J. Kowalczyk, William R. Clark, et al.. (2012). Hemodynamic Effects of Once-daily Tadalafil in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant α1-Adrenergic Antagonist Therapy: Results of a Multicenter Randomized, Double-Blind, Placebo-controlled Trial. Urology. 79(4). 875–882. 25 indexed citations

20.

Hilt, Dana, Maria S. Gawryl, Gerhard Koenig, Nancy Dgetluck, & Hans J. Moebius. (2012). O4‐12‐04: EVP‐6124, a selective alpha‐7 partial agonist, has positive effects on cognition and clinical function in mild‐to‐moderate Alzheimer's disease patients: Results of a six‐month, double‐blind, placebo controlled, dose ranging study. Alzheimer s & Dementia. 8(4S_Part_20). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact